Karuna Therapeutics - KRTX Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRTX shares.
View KRTX analyst ratings or view top-rated stocks.

15 equities research analysts have issued 12-month target prices for Karuna Therapeutics' stock. Their KRTX share price forecasts range from $183.00 to $330.00. On average, they expect the company's share price to reach $262.75 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts.

Karuna Therapeutics' stock was trading at $196.50 at the beginning of the year. Since then, KRTX shares have decreased by 0.4% and is now trading at $195.69.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our KRTX earnings forecast.

Karuna Therapeutics, Inc. (NASDAQ:KRTX) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($1.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.47) by $0.25.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

(KRTX) raised $70 million in an initial public offering (IPO) on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Karuna Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Clarius Group LLC (0.32%), Emerald Advisers LLC (0.29%), TD Asset Management Inc (0.29%), Emerald Mutual Fund Advisers Trust (0.23%), New York State Common Retirement Fund (0.20%) and Catalyst Private Wealth LLC (0.06%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends.

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KRTX stock can currently be purchased for approximately $195.69.

Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $6.72 billion and generates $36.96 million in revenue each year. The company earns $-143,800,000.00 in net income (profit) each year or ($7.44) on an earnings per share basis.

The company employs 118 workers across the globe.

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com.